Introduction
Recombinant adenovirus (Ad) has been used in a number of biological assays as well as human gene therapy trials for inherited disorders and cancer. [1] [2] [3] [4] [5] [6] One reason for their potential applicability to treatment of human disease is that they are amenable to commercial production. However, the fact that they can be generated in high titers and in large amounts is offset by their immunogenicity and antigenicity in vivo. Currently, these characteristics limit their use in treatment of human disease.
Recombinant Ad can be made devoid of viral genes, [7] [8] [9] reducing cytotoxic T cell responses to transduced cells when tested in mice. In studies in non-human primates, transgene expression in vivo from vectors deleted of viral coding sequences persists many months in liver. 10 At some point, however, loss of adenoviral DNA, which exists as an episome, 11 would require readminstration of the vector. Neutralizing immune responses against adenovirus capsid proteins preclude successful readministration in many tissues. [12] [13] [14] [15] Recently, studies have shown that adenoviruses can be modified or formulated so that infection can occur in the presence of neutralizing antibodies. 16 , 17 Gall and colleagues 18 showed that switching of fiber sequences between vectors administered sequentially allows for reinfection in previously immunized animals. Thus, repetitive in vivo administration of adenovirus devoid of viral genes would be accomplished by using a series of viruses containing the same therapeutic gene, but different capsid proteins. As an alternative to this approach, we 16 and 17 have shown that neutralizing anti-adenovirus antibodies are less capable of inhibiting infection if the virus is first subjected to polymer encapsulation with PLGA 16 or complexation with poly-l-lysine, or lipids. 17 In addition to rendering the adenovirus less susceptible to inactivation by neutralizing antibodies, our previous work showed that the encapsulation of adenovirus in PLGA reduced the antigenicity of the adenovirus following in vivo delivery. But the process of encapsulation was inefficient; only 10% of input virus became associated with the microspheres, with only 10% of the encapsulated virus released. In this study we designed experiments to test if aspects of encapsulation, release of virus, or efficiency of infection after release could be improved.
Results
We first asked how changing the energy source required for formation of the primary emulsion affected microencapsulation of adenovirus. Ad␤gal was added to PLGA dissolved in methylene chloride and the mixture sonicated for various times and power outputs. These preparations were compared with standard methods of microencapsulation using vortexing for their ability to release viable virus using a gene transfer assay. Our data show that sonication did not significantly increase the amount of viable virus released from the spheres over 48 h compared with vortexed samples (Figure 1) . Samples prepared by vortexing yielded 41 000 ± 3000 light units per microgram protein while sonicated preparations were either slightly worse (eg preparation at 50 W, 15 s) or showed modest increases. Spheres prepared by sonicating released less virus than when prepared by vortexing when cumulative release was quantified over a 96-h time period (data not shown).
Vortexing produced spheres that were transparent, with a sphere-inside-of-sphere morphology when viewed under the light microscope ( Figure 2A ). In contrast, spheres prepared by sonication were homogeneously dense ( Figure 2B ). Under SEM, the external morphology of microspheres made using sonication were smooth ( Figure 2C ), similar to those made by vortexing. 16 The average sphere size for both preparations was approximately 100 m. Increasing amounts of polyvinyl alcohol (PVA) used in the formation of the first emulsion from 3 to 10% modestly increased the overall yield of virus released as measured indirectly by gene transfer assay ( Figure 3) . By substituting polyvinyl pyrrolidone (PVP) for PVA, gene transfer increased seven-fold over formulation of adenovirus with 3% PVA in the emulsion. All preparations continued to release virus over the 7 days of the study, with the cumulative release highest for virus encapsulated in 10% PVP.
We next asked if co-encapsulation of virus with polyl-lysine would allow for increased encapsulation and/or increased efficiency of gene transfer after release of virus from the microspheres. Microspheres were prepared with increasing PLL to viral particle ratios and DNA isolated from aliquots of microspheres by phenol:chloroform extraction to test effects of PLL on encapsulation efficiency. Isolated DNA was transferred to nitrocellulose membranes and probed with a radiolabeled DNA fragment specific for the E. coli LacZ gene present in the adenovirus vector. The inclusion of PLL did not measurably alter the amount of virus encapsulated into microspheres ( Figure 4) .
Addition of PLL to virus before encapsulation increased the efficiency of gene transfer in 9L cells, but not HeLa cells ( Figure 5 ). ␤-Galactosidase activity increased by three orders of magnitude in 9L cells incubated in spheres containing a PLL:Ad␤gal ratio of 2500 compared with a ratio of zero (Figure 5a ). Increasing the PLL:viral ratio over the same range resulted in less than three-fold differences in gene transfer to HeLa cells ( Figure 5b ). These data supported our previous result ( Figure 4 ) that PLL did not increase the overall yield of virus encapsulated and released.
The release kinetics of PLGA microspheres are largely defined by the lactide:glycolide ratio, 19 suggesting that precomplexing the virus with PLL should not effect the rate of virus release from the spheres, or how long the spheres continue to release viable virus. To test this, we examined the release of virus over 96 h from microspheres made with Ad␤gal complexed with 0, 2500, or 5000 PLL molecules to viral particle. Medium containing the released virus was tested for viability by transduction assay on 9L cells. Increasing the PLL/Ad␤gal ratio resulted in increased gene transfer as expected, but the peak time at which infectious virus was released was the same for all preparations ( Figure 6 ).
The PLL/viral microsphere preparations were collected after 96 h of incubation and added directly to 9L cells. ␤-Galactosidase activity assay 48 h later indicated that viable virus continued to be released (Figure 7 ), although at much lower levels than freshly prepared spheres. Interestingly, the total amount of viral DNA released over the cumulative 192 h was quite low. This contrasts the 10% approximated release of virus encapsulated under similar conditions but in the absence of PLL. Differences could be solely reflective of PLL, or may also reflect the sensitivity of the slot blot assay. When measured by slot blot assay, the amount of DNA isolated from fresh microspheres was found to be not significantly different to that harvested after 192 h (data not shown).
Free, unbound PLL gives a strong positive signal at 129 m/z, which disappears upon association of the PLL with the adenovirus particles. To examine the PLL:Ad␤gal association, a HPLC/mass spectrometry assay was developed using the 129 + m/z signal as an indicator of unbound PLL. Preparations of PLL, with and without virus, were passed through a 5-mm C-18 HPLC column and the column effluents analyzed by mass spectrometry. Figure 8 shows a typical result. In the absence of virus, the material eluting from the column contained considerable quantities of the 129 + m/z signal. However, when an equivalent amount of PLL was premixed with Ad␤gal at a PLL:virus particle ratio of 500:1, the 129 + m/z signal was eliminated. By varying the PLL to virus ratio, we could then detect the point at which free, unbound PLL was present in the preparations, thereby titering the PLL:Ad␤gal interaction. As seen in Figure 9 , free PLL was detected in preparations where the PLL:Ad␤gal ratio 
Discussion
Biodegradable microspheres have been used to deliver drugs at a controlled rate to target specific organs includ-ing the brain. [20] [21] [22] [23] The polymers used in the manufacture of microspheres include albumen, starch and co-polymers of lactide and glycolide (PLGA). 19, 20 PLGA microspheres undergo slow degradation by hydrolysis of ester linkages to yield lactic and glycolic acid. Our previous studies demonstrated the feasibility of encapsulating recombinant adenovirus into PLGA microspheres with retention of virus viability. 16 In this study, we tested methods to increase the amount of virus encapsulated and/or the amount of virus released, and if the transduction efficiency of the input virus, once released, could be improved.
We previously showed that adenovirus formulated in PLGA microspheres is released in two phases, an initial burst release followed by a slow, continuous release. 16 Earlier work by Igartua et al 24 showed that sonicationinduced emulsification could reduce the amount of product shed from the spheres during the initial 24 h, compared with microspheres prepared by vortexing. Our data suggest that for several of the conditions tested, more virus is released in the initial 24 h in PLGA-encapsulated adenovirus made by sonication versus vortexing. However, the differences in release of viable virus as measured by gene transfer were less than two-fold. In contrast to the 24 h data, the cumulative release of virus over 8 days continued to be lower for preparations that underwent sonication. A possible explanation for this effect may be that sonication induced degradation of the virus. This was previously noted when sonication was used to make PLGA-encapsuled trypsin. 25 The stabilizer in the external aqueous phase of the water-in oil-in water prepared microspheres can effect the amount of protein loaded and plays an important role in formation of the oil/water droplet within the water/oil/water mixture. 26 Because these agents contain both hydrophobic and hydrophilic domains, 27 they play an important role in the viral encapsulation process by forming a film barrier between the organic and aqueous interfaces in the double emulsion. This barrier stabilizes the emulsion and prevents the coalescence of the two phases as the organic solvent is removed. Thus, as the organic phase is removed, solid microparticles are formed. 26, 28 In experiments presented here we found that increasing the concentration of surfactant from 3 to 10% improved the yield of virus released. Also, substituting PVP for PVA resulted in a seven-fold increase in gene transfer. Coombes et al 26 in examining ovalbumin encapsulation in PLGA microparticles under 5 microns, reported that the use of PVP versus PVA increased overall protein loading due to the better film properties of PVP. Although the particles in our system were significantly larger, it is possible that PVP allowed for more virus to be encapsulated into the microspheres.
The release profile of the compound from a polymer encapsulation is dependent upon the polymer and compound being encapsulated. 19, 29, 30 As previously noted, the characterization of the release is in at least two phases. The first phase is a rapid release of the compound as a result of diffusion from the surface of the microspheres. The second phase is relatively slow release with the erosion of the polymer from hydrolysis. 29 Some investigators also characterize a third phase: increased release at the time of significant erosion of the microsphere(2633). Recombinant adenovirus encapsulated in PLGA microspheres with or without previous complexation with PLL illustrated characteristics of quick release followed by a diminished release over a prolonged time period. Adenovirus-microspheres in vivo could supply a 'loading dose' of a gene product, followed by low-level 'repeat dosing' as the polymer slowly erodes.
Although modest changes were noted with sonication or alteration of surfactant concentrations or makeup, the most dramatic increase in gene transfer efficiency resulted when the adenovirus was complexed with PLL before encapsulation. Our data suggest that gene transfer increased due to a direct effect of the PLL on receptorindependent adenovirus-mediated gene transfer. This was first described by Fasbender and colleagues. 31 They found that PLL added to recombinant adenovirus, dramatically increased gene transfer to 9L gliosarcoma cells, and that, in primary hepatocytes, gene transfer with PLL:Ad was not inhibited by the addition of excess fiber protein. In experiments described here, we found that PLL did not allow for more virus to be encapsulated, nor did it alter the parameters of virus release. Rather, PLL increased the efficiency of gene transfer once eroded or released from the microsphere. We speculate that as the encapsulation procedures are further improved to reduce the time to polymer erosion, in vivo applications of PLGA-encapsulated adenovirus can be tested.
Materials and methods
Cell culture HeLa cells were grown in Eagle's MEM (Sigma Cell Culture, St Louis, MO, USA) supplemented with 10% fetal calf serum (FCS), 1% non-essential amino acids, 100 U/ml penicillin and 100 g/ml streptomycin. 9L cells were grown in Dulbecco's modified Eagle's medium (DMEM, Gibco BRL) supplemented with 10% FCS, 1% non-essential amino acids, 100 U/ml penicillin, 100 g/ml streptomycin, and sodium pyruvate.
Recombinant adenovirus propagation
Virus was propagated by the University of Iowa Gene Transfer Vector Core. HEK 293 cells were grown in DMEM supplemented with 10% FCS. Virus was propagated using routine methods. 32 The cells were infected with 5 × 10 8 iu/150 cm plate and cells harvested upon cytopathic effect and the virus purified, desalted and diluted to a final concentration of 1 × 10 12 pt/ml in 50% glycerol, 100 mg/ml BSA. The adenovirus, AdRSVnt␤ga-lactosidase (Ad␤gal), contains a coding sequence for nuclear-targeted E. coli ␤-galactosidase and has been previously described. 33 
PLGA encapsulation of recombinant adenovirus
Standard protocol: 200 mg of 75/25 DL-PLGA (MW 9400, Birmingham Polymers, Birmingham, AL, USA) was dissolved in 1 ml of methylene chloride 20% w/v in a 1.5 ml microcentrifuge tube. Fifty l input volume containing Ad␤gal was added to the dissolved polymer while vortexing. Mixing was continued for an additional 30 s. This first emulsion was added to 2 ml of 1 to 10% polyvinyl alcohol (PVA) (average MW 30 000 to 70 000, Sigma Biochemicals, St Louis, MO, USA) or 10% polyvinyl prryolidine in water with continuous vortexing for 30 s. The resultant double emulsion was poured into 100 ml of 5% isopropyl alcohol with continuous stirring for 30 min-1 h to extract the methylene chloride. The microspheres were harvested by gentle centrifugation at 200 g and rinsed five times in PBS. Spheres were resuspended to a final volume of 1 ml in PBS and used immediately or frozen at −20°C.
PLL/PLGA encapsulation: Poly-l-lysine (PLL hydrobromide. MW 56 000, Sigma Biochemicals) was stored as a 50 g/l stock solution in water at −20°C. The amount of PLL necessary to achieve ratios of PLL molecules to viral particles of 50:1 to 7500:1 was calculated using the average MW (56 000). The appropriate dilution of PLL stock solution was made with PBS. This was added to an equal volume of Ad␤gal and incubated at room temperature for 15 min. After the incubation, an equal volume of 100 mg/ml BSA in 50% glycerol was added to the Ad/PLL mixture. Fifty l of this solution was used as the input aqueous volume and added to the organic PLGA solution while vortexing to form the inner water in oil emulsion. Additional procedures were as in the standard protocol.
Encapsulation by sonication: Fifty l of input volume containing 25 l of Ad␤gal and 25 l of 100 mg/ml BSA in 50% glycerol was added to the dissolved polymer and was probe sconicated (Model GE 50, Ultrasonic Processor 50 W model, Deerfield, IL, USA) to form the first emulsion. This was then added to PVA and vortexed. The standard protocol was followed hereafter.
Adenoviral release assay:
To measure viral release from microsphere preparations, a 0.75 ml aliquot of DMEM with 2% FCS (release medium) was added to a measured quantity of encapsulated virus microspheres and incubated at 37°C. The microsphere release medium was replaced every 24 h. For the 0 h time-point, a 0.75 ml aliquot of DMEM with 2% FCS was added to the microspheres and removed immediately. To assay for released adenovirus, the media containing the adenovirus was added to individual wells of a 24-well plate containing indicator cells (9L or HeLa) at approximately 50% confluency. The infected cells were incubated for an additional 48 h and ␤-galactosidase activity determined by chemiluminescence using the Galactolight Plus assay (Galacto-Light Plus kit, Tropix, Bedford, MA, USA) following the manufacturer's directions. The chemiluminescence was determined with a luminometer (Monolight 2010, Analytical Luminescence Laboratory, Ann Arbor, MI, USA) and background values of controls subtracted from experimental readings. Samples were heat inactivated at 48°C for 50 min before the reaction to remove any endogenous galactosidase activity. Protein assays were performed (Bio-Rad DC Protein Assay, BioRad Laboratories, Hercules, CA, USA) and read in a Thermomax MicroPlate Reader (Molecular Devices, Sunnyvale, CA, USA) at 750 nm. For certain experiments, freshly prepared microspheres were immediately placed on to a plate of 9L cells and incubated for 48 h at 37°C. Alternatively, they were incubated in release medium for specified time periods with media rinses every 24 h before the microsphere preparations were placed directly on to the 9L indicator cells.
Slot blot hybridization analysis: DNA was extracted from microsphere aliquots by phenol:chloroform extraction, transferred on to nitrocellulose, and membranes hybridized with a DNA fragment specific for E. coli LacZ sequences. The DNA template for the probe was made by PCR from bp 2654 to bp 3151 of Ad␤gal, which is in the LacZ coding region, following the manufacturer's recommendations (Prime-It RmT Random Primer Labeling Kit, Stratagene, La Jolla, CA, USA). Autoradiography was done using Kodak BioMax film with exposure at −80°C.
Electron microscopy: For scanning electron microscopy, PLGA encapsulated virus was freeze-dried and then mounted on to aluminum stubs and sputter-coated in an Emitech K550 sputter coater with a gold/palladium target. Samples were viewed with an Hitachi S-4000 scanning electron microscope with a field emission electron source. 34 HPLC/Mass spectrometry (LC/MS) analysis: The samples to be quantified using the LC/MS were prepared by the addition of different concentrations of PLL to a standard virus solution to attain a range of PLL:viral particle ratios (10 6 , 5 × 10 5 , 10
5
, 5 × 10 4 , 10 4 5 × 10 3 , 10 3 , 500, 100, or 50 to 1). The adenovirus content in each sample was 10 9 particles. Samples were diluted to 1 ml with 50:50 acetylnitryl:water. Initial HPLC separation was performed with a Hewlett Packard HPLC System Model 1100 HP. Samples (10 l injection volume) were passed through a 5 mm C-18 column, with a 1 mm C-18 pre-column, in a mobile phase of 50/50 acetonitrile:water at a flow rate of 0.1 ml/min. The typical run time was 3 min. Effluent from the LC column was introduced to a Micromass Quattro II triple-quadrupole mass spectrometer (Beverly, MA, USA) using an electrospray ionization (ESI) probe. For this analysis, positive ionization mode was used. Samples were analyzed using single ion recording (SIR) acquisition mode. The peak resolution and response at +129 m/z (PLL's major peak) of the test compound was initially optimized by adjusting the general tuning parameters and gas flow rates. The optimum conditions were as follows: cone voltage 100 V, capillary voltage 3.5 V, drying gas 200 L/h, HV lens voltage 0.5 kV, source temperature 150°C. The concentration of the free PLL in the preparations was obtained from standard curves generated from LC/MS analysis of pure preparations of PLL under the same conditions as used for analysis of the mixed samples. The mass to charge peak used to quantify the PLL was +129.0 m/z. From these data, the amount of free poly-l-lysine in each ratio sample was determined.
